Mind Medicine (MindMed) Inc (MNMD)

[namah sivaya]

Good morning. article says MMEDF price target $32.50 with trial success... I’ll settle for $30 personally :)


....The World Health Organization estimates that 284 million people are living with anxiety disorders around the globe. And it's the most common mental illness in the United States.

Fifty percent of ADHD patients suffer from anxiety disorders. And according to MindMed's website, "up to 90% of patients with generalized anxiety disorder have symptoms of another mental health problem, such as depression or substance abuse."

Speaking of substance abuse, MindMed's website also states that the opioids cost the United States alone $500 billion per year. That's a massive industry that's ripe for disruption.

There haven't been new painkiller medicines developed in 37 years. And psychedelic medicines combined with the professional therapy MindMed provides with Project Layla could very well be the answer.

At $3.25 per share, MMEDF is only a small-cap $1 billion business.

That's peanuts in the grand scheme of things. The risk/reward for investors is definitely worth paying attention to.

If MindMed is successful in these phase 2 trials and then phase 3, the company's stock could be worth a whole lot more than it is today.

MindMed could easily be worth 10x what it is today (a $10 billion company worth $32.50 per share) if one or more phase 3 trials are successful.

What is clear above all else is that we are in the very early stages of the psychedelic medicine industry.

There's no doubt that the risks are still high, but the rewards for investors with open minds willing to do the research could be absolutely massive.




https://moneymorning.com/2020/12/22/the-best-psychedelic-stocks-can-10x-your-money/